BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26428374)

  • 21. Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
    Cooper L; Longnecker R
    Antiviral Res; 2002 Dec; 56(3):219-31. PubMed ID: 12406506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
    Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
    Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.
    Rechsteiner MP; Berger C; Zauner L; Sigrist JA; Weber M; Longnecker R; Bernasconi M; Nadal D
    J Virol; 2008 Feb; 82(4):1739-47. PubMed ID: 18057232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling.
    Ikeda M; Longnecker R
    Virology; 2009 Mar; 385(1):183-91. PubMed ID: 19081591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.
    Chen HS; Martin KA; Lu F; Lupey LN; Mueller JM; Lieberman PM; Tempera I
    J Virol; 2014 Feb; 88(3):1703-13. PubMed ID: 24257606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Latent Membrane Protein 1 (LMP1).
    Kieser A; Sterz KR
    Curr Top Microbiol Immunol; 2015; 391():119-49. PubMed ID: 26428373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
    Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
    J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
    Longnecker R
    Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction.
    Fruehling S; Longnecker R
    Virology; 1997 Sep; 235(2):241-51. PubMed ID: 9281504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A.
    DeKroon RM; Gunawardena HP; Edwards R; Raab-Traub N
    mBio; 2018 Jun; 9(3):. PubMed ID: 29921667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility.
    Allen MD; Young LS; Dawson CW
    J Virol; 2005 Feb; 79(3):1789-802. PubMed ID: 15650203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor.
    Ingham RJ; Raaijmakers J; Lim CS; Mbamalu G; Gish G; Chen F; Matskova L; Ernberg I; Winberg G; Pawson T
    J Biol Chem; 2005 Oct; 280(40):34133-42. PubMed ID: 16087662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
    Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
    Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection.
    Wasil LR; Tomaszewski MJ; Hoji A; Rowe DT
    PLoS One; 2013; 8(1):e54010. PubMed ID: 23308294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.
    Longnecker R; Kieff E
    J Virol; 1990 May; 64(5):2319-26. PubMed ID: 2157888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.
    Incrocci R; McCormack M; Swanson-Mungerson M
    J Gen Virol; 2013 May; 94(Pt 5):1127-1133. PubMed ID: 23303827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The LMP2A protein of Epstein-Barr virus regulates phosphorylation of ITSN1 and Shb adaptors by tyrosine kinases.
    Dergai O; Dergai M; Skrypkina I; Matskova L; Tsyba L; Gudkova D; Rynditch A
    Cell Signal; 2013 Jan; 25(1):33-40. PubMed ID: 22975684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).
    Rochford R; Miller CL; Cannon MJ; Izumi KM; Kieff E; Longnecker R
    Arch Virol; 1997; 142(4):707-20. PubMed ID: 9170499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
    Portis T; Longnecker R
    Oncogene; 2004 Nov; 23(53):8619-28. PubMed ID: 15361852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.
    Merchant M; Swart R; Katzman RB; Ikeda M; Ikeda A; Longnecker R; Dykstra ML; Pierce SK
    Int Rev Immunol; 2001; 20(6):805-35. PubMed ID: 11913951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.